Company: APM
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001213900-25-037669
Chunk: 45

Company: Aptorum Group Ltd
Filing Date: 2025-04-30
Form: 20-F
Item: Item 3
Chunk 45
---
 able to effectively
expand our organization by hiring new employees, outsourcing works or expanding our groups of consultants and contractors, we may not
be able to successfully implement the tasks necessary to further develop and commercialize our drug and diagnostics technology candidates
and, accordingly, may not achieve our research, development and commercialization goals.

We intend to seek additional collaborations,
strategic alliances or acquisitions or enter into royalty-seeking or sublicensing arrangements in the future, but we may not realize the
benefits of these arrangements.

We intend to form or seek
strategic alliances, create joint ventures or collaborations, acquire complimentary products, IP rights, technology or businesses or enter
into additional licensing arrangements with unrelated parties that we determine may complement or augment our development and commercialization
efforts with respect to our drug and diagnostics technology candidates. Any of these relationships may require us to incur non-recurring
and other charges, increase our near and long-term expenditures, issue securities that dilute our existing shareholders, or disrupt our
management and business.

We will face significant competition
in seeking appropriate strategic partners and the negotiation process is likely to be time-consuming, costly and complex. Moreover, we
may not be successful in our efforts to establish a strategic partnership or another alternative arrangement for any of our drug and diagnostics
technology candidates because their state of development may be deemed to be too early for collaborative effort and others may not view
our drug candidates as having the requisite potential to demonstrate safety and efficacy. If and when we enter into an agreement with
a collaboration partner or sublicensee for development and commercialization of a drug or diagnostics technology candidate, we can expect
to relinquish some or all of the control over the future success of that drug candidate to the unrelated-party.

Further, even if we enter
into a collaboration involving any of our drug and diagnostics technology candidates, the arrangement will be subject to numerous risks,
which may include the following:

  the collaborators will likely have significant discretion in determining the efforts and resources that they will apply to a collaboration;                                                           
  the collaborator may ultimately choose not pursue development and commercialization of our drug or diagnostics technology candidates or may elect not to continue or renew development or commerc...  

  the collaborator may delay clinical trials, provide insufficient funding for a clinical trial, stop a clinical trial, abandon a drug or diagnostics technology candidate, repeat or conduct new c...  
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────